RENEW · Hormone and cellular care
GHK-Cu/Epithalon Injection
Two ingredients. One careful evaluation.
This formulation combines GHK-Cu and epithalon. Understanding each ingredient is only the beginning of evaluating the blend.
Prescription required. Provider evaluation determines eligibility.
GHK-Cu is a copper-binding peptide; epithalon is a synthetic tetrapeptide. A combination formulation is distinct from either component alone.
The ingredients have been studied in different biological contexts. Separate ingredient research does not establish the effectiveness of an injected combination.
Instructions depend on the exact injectable preparation. Review ingredient forms, strength, preparation and administration with your prescriber and pharmacy.
The review should include a clear clinical rationale, evidence for the exact blend, medicines, health history and formulation-specific risks.
Distinct ingredients.
No assumed synergy.
GHK-Cu is a copper-binding peptide; epithalon is a synthetic tetrapeptide. A combination formulation is distinct from either component alone.
-
Distinct ingredients
Copper peptide and epithalon in one formulation.
-
Combination evidence
Ingredient research does not prove blend performance.
-
No assumed synergy
More than one ingredient does not guarantee more benefit.
Care starts with
understanding you.
A treatment decision should take your health history, current medications and goals into account. Your evaluation is the place to discuss questions, potential risks and whether another approach may be more appropriate.
-
Your health in context
Share your medical history, current medications and treatment goals.
-
A considered decision
Discuss the evidence, potential risks and available alternatives.
-
Clear next steps
If treatment is prescribed, follow the instructions for your exact medication and ask how follow-up will work.
Explore your options
with context.
Different treatments have different uses, risks and levels of evidence. Explore this care category, then discuss the options that may fit your clinical needs.
Explore hormone and cellular care-
Sermorelin
Sermorelin is related to growth-hormone-releasing hormone.
Sermorelin is a synthetic fragment of growth-hormone-releasing hormone. It is different from taking growth hormone itself.
Learn more -
Tesamorelin
Approved use concerns HIV-associated lipodystrophy.
Tesamorelin is a growth-hormone-releasing factor analog. Approved Egrifta products are indicated for excess abdominal fat in adults with HIV-associated lipodystrophy.
Learn more -
CJC/Ipamorelin
The precise CJC identity must be specified.
CJC-related peptides and ipamorelin are different substances. The CJC form, including whether it contains a drug affinity complex, must be identified.
Learn more
A plan begins with
an evaluation.
Completing an assessment does not guarantee a prescription.
-
Share your history
Provide information about your health, medications and goals.
-
Review the options
A licensed provider evaluates whether treatment is clinically appropriate. Further information, testing or another type of care may be needed.
-
Understand your prescription
If prescribed, review the medication, administration directions, risks and follow-up plan before starting.
-
Revisit the plan
Discuss your response and any concerns with your prescriber. Do not change a dose or combine treatments on your own.
Know the important
information.
Every medication has potential risks. Review the complete safety information for the exact product and tell your provider about your medical conditions, allergies, pregnancy or pregnancy plans, and all medicines and supplements you take.
Compounded medications are not FDA-approved. FDA does not evaluate these preparations for safety, effectiveness or quality before marketing.
Human safety data may be incomplete. Ingredient identity, purity, formulation and administration route matter; an ingredient’s research history does not establish the safety of a blend.
Seek emergency care for trouble breathing or swelling of the face, lips or throat. Contact a clinician promptly for severe or concerning symptoms. Do not rely on routine online messaging for an emergency.
Frequently asked questions
No. The additional ingredient creates a different formulation.
That outcome is not established for the proposed injection.
Not necessarily. A benefit must be supported for the specific combination.
A licensed provider considers your health history, current medications, clinical needs and the evidence for the specific treatment. Further testing or a different type of care may be recommended.
No. A prescription is provided only when the evaluating provider determines that treatment is medically appropriate and available.
Follow your prescriber and pharmacy's instructions for the exact product. Ask before changing a dose, switching formulations or combining treatments.
Your next step starts with your
health.
Share your history and goals so a licensed provider can evaluate which care options may be appropriate for you.
Prescription required. Treatment is not appropriate for everyone. Assessment does not guarantee a prescription.